ReviewFrontiers in immunology2026
Gut microbiota modulation in the prevention and treatment of heat stroke.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, heat stroke (HS) have been reported with increasing frequency, and this trend is hard to separate from broader environmental changes, including climate change, recurrent extreme heat events, and air pollution. When people are exposed to high-temperature environments for a prolonged period, especially during intense physical activity, the condition may progress to HS. HS is an acute and potentially fatal disorder that can deteriorate rapidly if not treated in time. The intestine appears to be particularly vulnerable during HS. HS can disrupt intestinal tight junctions and weaken the barrier function of the gut, leading to what is commonly described as a "leaky gut." Once this barrier is compromised, microbial products such as lipopolysaccharides can enter the bloodstream. These molecules may then activate immune cells, promote excessive cytokine release, and eventually drive a systemic inflammatory response. In severe cases, this inflammatory process can develop into systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS). Current evidence increasingly suggests that intestinal injury is not simply a secondary result of HS. Rather, it may serve as an important early event in the development and progression of the disease. Still, it should be noted that much of the available evidence comes from preclinical studies, and strong clinical confirmation is still limited. Probiotics have attracted attention because they may help reduce the occurrence and severity of HS by maintaining gut microbiota balance and regulating intestinal immune responses. However, since most supporting data are still derived from animal experiments, their protective effects in humans need to be interpreted carefully. Another point worth emphasizing is that the gut is not working alone. Through gut-organ communication networks, the intestinal microbiota can interact with distant organs, including the liver, lungs, and brain. These gut-liver, gut-lung, and gut-brain axes may help explain how HS leads to injury beyond the intestine itself. In this review, we summarize current findings on how modulation of the gut microbiota may improve intestinal thermotolerance and strengthen barrier function, with the aim of providing useful insights for the prevention and treatment of HS in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.